Antipsychotic-Like Effects of the Selective Rho-Kinase 2 Inhibitor KD025 in Genetic and Pharmacological Mouse Models of Schizophrenia

Why It Matters

Targeting ROCK2 could deliver effective symptom relief while avoiding the cardiovascular and metabolic side effects that limit current antipsychotics, addressing a major unmet need in schizophrenia care.

Key Takeaways

• KD025 improves cognition in mouse schizophrenia models
• Restores prefrontal cortex spine density via ROCK2 inhibition
• Shows antipsychotic efficacy without hypotension
• Does not induce EPS or hyperprolactinemia
• High doses modestly raise blood glucose

Pulse Analysis

Schizophrenia treatment has long been hampered by drugs that blunt positive symptoms but leave negative and cognitive deficits largely untouched, while exposing patients to weight gain, diabetes, and movement disorders. Recent genomic work linking ARHGAP10 loss‑of‑function to heightened RhoA‑ROCK signaling has highlighted the pathway as a mechanistic bridge between genetic risk and synaptic pathology. ROCK2, the brain‑predominant isoform, regulates actomyosin dynamics that shape dendritic spines, making it an attractive target for restoring the cortical circuitry that underlies cognition.

Preclinical data now show that KD025, a selective ROCK2 inhibitor already approved for chronic graft‑versus‑host disease, penetrates the mouse brain and normalizes the hyper‑phosphorylation of MYPT1, a downstream ROCK substrate. In mice carrying schizophrenia‑associated ARHGAP10 mutations, KD025 reversed methamphetamine‑induced spine loss and rescued performance on a touchscreen visual‑discrimination task, a proxy for executive function. Similar benefits were observed in wild‑type mice challenged with MK‑801, while the drug left locomotor activity and motivation untouched. Importantly, KD025 avoided the pronounced hypotension seen with fasudil and did not trigger extrapyramidal signs or prolactin elevation, side effects that drive non‑adherence to first‑ and second‑generation antipsychotics.

The translational promise of KD025 lies in its dual profile of efficacy and tolerability. By focusing on ROCK2 rather than the broader ROCK1/2 inhibition of fasudil, the compound may sidestep vascular side effects while still modulating synaptic architecture. However, chronic dosing studies, human safety assessments, and exploration of broader symptom domains such as sensorimotor gating are needed before clinical trials can be justified. If these hurdles are cleared, ROCK2 inhibition could carve out a novel niche in the schizophrenia market, offering clinicians a tool that targets cognitive impairment without the metabolic and motor liabilities of existing therapies.